

NEXT SCIENCE®

Update on XPerience Surgical Rinse FDA approval process

Sydney, Australia Monday, 7 September 2020, Next Science Limited (ASX:NXS) (**Next Science**) announces an update on the FDA approval process in relation to its XPerience Surgical Rinse.

Next Science has received written notification from the FDA of additional requirements to obtain a 510(k) Class II clearance for XPerience. To demonstrate substantial equivalence, the FDA requires Next Science to undertake a further animal study and a further laboratory test.

Having anticipated these requirements, Next Science has already set the additional study and test in motion and expects they will be completed in time to enable it to lodge a 510(k) Class II FDA submission in November 2020, setting the expected timing for the US launch of XPerience to H1 2021. This timing is consistent with our communication to the market on 26 August 2020 when we released our half year results.

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

Approved and authorised for release by Next Science's Chairman.

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as "believes", "considers", "could", "estimates", "expects", "intends", "may", and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.